Literature DB >> 9266724

Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity.

T Kihara1, S Shimohama, H Sawada, J Kimura, T Kume, H Kochiyama, T Maeda, A Akaike.   

Abstract

beta-Amyloid (A beta), a major constituent of senile plaques in Alzheimer's disease (AD), is thought to contribute to the neurodegeneration. We examined the effects of nicotinic receptor agonists on A beta cytotoxicity in cultured rat cortical neurons. The number of viable neurons decreased significantly when cultures were exposed to synthetic A beta peptides (25-35). Concomitant administration of nicotine with A beta markedly reduced the number of dead cells. This nicotine-induced neuroprotection was dependent on the concentration. When hexamethonium or mecamylamine, nicotinic antagonist, was added, neuroprotective effect of nicotine was blocked, which indicates that effect of nicotine was mediated by nicotinic receptors. In addition, a selective alpha7-receptor antagonist, alpha-bungarotoxin (alpha-BTX), blocked the neuroprotective effect of nicotine. Furthermore, incubation with 3-(2,4)-dimethoxybenzylidene anabaseine (DMXB), a selective alpha7-receptor agonist, protected against A beta-induced neuronal death. These results suggest that alpha7-receptor activation plays an important role in neuroprotection against A beta cytotoxicity. This study suggests that nicotinic receptor stimulation, especially alpha7-receptor activation, may be able to protect neurons from degeneration induced by A beta and may have effects that counter the progress of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266724     DOI: 10.1002/ana.410420205

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  61 in total

1.  The single-channel properties of human acetylcholine alpha 7 receptors are altered by fusing alpha 7 to the green fluorescent protein.

Authors:  Sergio Fucile; Eleonora Palma; Ataulfo Martinez-Torres; Ricardo Miledi; Fabrizio Eusebi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

2.  Some properties of human neuronal alpha 7 nicotinic acetylcholine receptors fused to the green fluorescent protein.

Authors:  Eleonora Palma; Anna M Mileo; Ataulfo Martinez-Torres; Fabrizio Eusebi; Ricardo Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 3.  The effects of dietary choline.

Authors:  Elisabetta Biasi
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

Review 4.  Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor.

Authors:  Wen-Yan Cui; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-13       Impact factor: 4.147

5.  Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects.

Authors:  Young-Hoon Sung; Deborah A Yurgelun-Todd; Douglas G Kondo; Xian-Feng Shi; Kelly J Lundberg; Tracy L Hellem; Rebekah S Huber; Erin C McGlade; Eun-Kee Jeong; Perry F Renshaw
Journal:  Am J Drug Alcohol Abuse       Date:  2015-04-14       Impact factor: 3.829

6.  Neuroprotection in Alzheimer's disease - new strategies for treatment.

Authors:  A Nordberg
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

7.  Boosting Endogenous Resistance of Brain to Ischemia.

Authors:  Fen Sun; Stephen R Johnson; Kunlin Jin; Victor V Uteshev
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

Review 8.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.

Authors:  Jun Kawamata; Syuuichirou Suzuki; Shun Shimohama
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

Review 10.  Tobacco smoking and MRI/MRS brain abnormalities compared to nonsmokers.

Authors:  E F Domino
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-09-11       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.